A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Public ClinicalTrials.gov record NCT03029832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of MOXR0916 in combination with atezolizumab versus placebo and atezolizumab in participants with locally advanced or metastatic urothelial carcinoma (UC) who have not received prior systemic therapy in the locally advanced/metastatic setting and who are ineligible to receive cisplatin-based therapy.
Study identification
- NCT ID
- NCT03029832
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2017 (Actual)
- Primary completion
- Apr 25, 2018 (Actual)
- Completion
- Apr 25, 2018 (Actual)
- Last update posted
- May 31, 2019
2017 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology - HOPE Wilmot | Tucson | Arizona | 85710 | — |
| University of Colorado | Denver | Colorado | 80045 | — |
| Yale University | New Haven | Connecticut | 06510 | — |
| Miami Cancer Institute of Baptist Health, Inc. | Miami | Florida | 33176 | — |
| University of Chicago; Hematology/Oncology | Chicago | Illinois | 60637 | — |
| Kansas City - Menorah Medical Center | Kansas City | Kansas | 66209 | — |
| Maryland Oncology Hematology, P.A. | Columbia | Maryland | 21044 | — |
| Nebraska Methodist Hospital; Cancer Center | Omaha | Nebraska | 68114 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| Columbia University Medical Center; Clinical Research Management Office | New York | New York | 10032 | — |
| Onc/Hem Care Clin Trials LLC | Cincinnati | Ohio | 45242 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Virginia Oncology Associates - Lake Wright Cancer Center | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03029832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2019 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03029832 live on ClinicalTrials.gov.